Karyopharm Therapeutics Inc. (KPTI) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Karyopharm Therapeutics I...

    NASDAQ: KPTI · Real-Time Price · USD
    6.60
    -0.14 (-2.00%)
    At close: Sep 05, 2025, 3:59 PM
    6.50
    -1.52%
    After-hours: Sep 05, 2025, 05:07 PM EDT

    Karyopharm Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 145.24M 146.03M 157.07M 209.82M
    Cost of Revenue
    		 6.01M 4.94M 5.21M 3.4M
    Gross Profit
    		 139.23M 141.09M 151.86M 206.42M
    Operating Income
    		 -119.44M -129.54M -142.2M -98.27M
    Interest Income
    		 7.4M 10.94M 2.36M 582K
    Pretax Income
    		 -76.36M -142.78M -164.92M -123.82M
    Net Income
    		 -76.42M -143.1M -165.29M -124.09M
    Selling & General & Admin
    		 115.44M 131.88M 145.4M 143.85M
    Research & Development
    		 143.23M 138.75M 148.66M 160.84M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 258.67M 270.63M 294.06M 304.69M
    Interest Expense
    		 37.42M 23.82M 25M 26.05M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 264.68M 275.57M 299.28M 308.09M
    Income Tax Expense
    		 57K 323K 369K 268K
    Shares Outstanding (Basic)
    		 8.12M 7.61M 5.46M 5.01M
    Shares Outstanding (Diluted)
    		 8.12M 7.61M 5.46M 5.01M
    EPS (Basic)
    		 -9.41 -18.79 -30.28 -24.75
    EPS (Diluted)
    		 -9.41 -18.79 -30.28 -24.75
    EBITDA
    		 -38.6M -118.42M -139.31M -96.98M
    EBIT
    		 -38.94M -118.95M -139.93M -97.77M
    Depreciation & Amortization
    		 340K 530K 621K 789K

    Add to Watchlist